LAUSR

The achievement of early and deep response is an essential step for improving the prognosis in acute lymphoblastic However, of safety for induction failure and poor early- response ALL. This empirical attempt may lay a foun-dation for employing venetoclax as a pre- emptive salvage regimen, to induce an early and deep remission and provide a chance for subsequent HSCT, which may further improve long- term outcomes for high- risk patients. The addition of venetoclax may be considered as a new therapeutic option for up- front/frontline salvage therapy, though larger groups of patients are needed to verify this.